These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 32657864)
1. 223Ra-Dichloride Response Evaluation Using 18F-Fluciclovine PET/CT and Bone Scintigraphy in a Patient With Castration-Resistant Metastatic Prostate Cancer. Wang J; Kuker R; Serafini A Clin Nucl Med; 2020 Nov; 45(11):e486-e488. PubMed ID: 32657864 [TBL] [Abstract][Full Text] [Related]
2. Benefit of 68Ga-PSMA-PET/CT in Patients Considered for 223Ra-Dichloride Therapy. Bode A; Rahbar K; Konnert J; Bögemann M; Stegger L Clin Nucl Med; 2016 Dec; 41(12):951-952. PubMed ID: 27749411 [TBL] [Abstract][Full Text] [Related]
3. Soft Tissue Response on 18F-Fluorocholine PET/CT in Metastatic Castrate-Resistant Prostate Cancer Treated With 223Ra-Dichloride: A Possible Abscopal Effect? Kwee SA; Lim J; Coel MN Clin Nucl Med; 2017 Nov; 42(11):868-871. PubMed ID: 28872544 [TBL] [Abstract][Full Text] [Related]
4. Comparison of 18F-Fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer. Chen B; Wei P; Macapinlac HA; Lu Y Nucl Med Commun; 2019 Sep; 40(9):940-946. PubMed ID: 31343613 [TBL] [Abstract][Full Text] [Related]
7. Baseline García Vicente AM; González García B; Amo-Salas M; García Carbonero I; Cassinello Espinosa J; Gómez-Aldaraví Gutierrez JL; Suarez Hinojosa L; Soriano Castrejón Á Clin Transl Oncol; 2019 Mar; 21(3):289-297. PubMed ID: 30006674 [TBL] [Abstract][Full Text] [Related]
8. Response Assessment of 223Ra Treatment: Should a Fluorocholine PET/CT Be Performed? García Vicente AM; Soriano Castrejón Á; Alvarez Cabellos R; Sanchez Gil B; Mohedano Mohedano N Clin Nucl Med; 2017 Oct; 42(10):761-765. PubMed ID: 28806246 [TBL] [Abstract][Full Text] [Related]
9. The Prognostic Value of Quantitative Bone SPECT/CT Before Dittmann H; Kaltenbach S; Weissinger M; Fiz F; Martus P; Pritzkow M; Kupferschlaeger J; la Fougère C J Nucl Med; 2021 Jan; 62(1):48-54. PubMed ID: 32444369 [TBL] [Abstract][Full Text] [Related]
10. The Relationship Between Total Lesion Activity on Filippi L; Basile P; Schillaci O; Bagni O Cancer Biother Radiopharm; 2020 Aug; 35(6):398-403. PubMed ID: 32109140 [TBL] [Abstract][Full Text] [Related]
11. Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience. Kairemo K; Milton DR; Etchebehere E; Rohren EM; Macapinlac HA Curr Radiopharm; 2018; 11(2):147-152. PubMed ID: 29956640 [TBL] [Abstract][Full Text] [Related]
12. Uptake of Radium-223 Dichloride and Early [ Letellier A; Johnson AC; Kit NH; Savigny JF; Batalla A; Parienti JJ; Aide N Mol Imaging Biol; 2018 Jun; 20(3):482-491. PubMed ID: 29027074 [TBL] [Abstract][Full Text] [Related]
13. Dizdarevic S; Jessop M; Begley P; Main S; Robinson A Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2264-2273. PubMed ID: 29998419 [TBL] [Abstract][Full Text] [Related]
14. Evaluating radium-223 response in metastatic castration-resistant prostate cancer with imaging. Iizuka J Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():16-23. PubMed ID: 30489033 [TBL] [Abstract][Full Text] [Related]
15. Poorly Differentiated Neuroendocrine Tumor With 18F-Fluciclovine Uptake in a Patient With Metastatic Castrate-Resistant Prostate Cancer. Abiodun-Ojo OA; Akintayo AA; Harik LR; Bilen M; Halkar RK Clin Nucl Med; 2021 May; 46(5):e282-e285. PubMed ID: 33208627 [TBL] [Abstract][Full Text] [Related]
16. Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival. Etchebehere EC; Araujo JC; Fox PS; Swanston NM; Macapinlac HA; Rohren EM J Nucl Med; 2015 Aug; 56(8):1177-84. PubMed ID: 26069307 [TBL] [Abstract][Full Text] [Related]
17. Superscan 18F-Fluciclovine PET/CT of PSA-Negative Prostate Cancer Bone Metastases. Chen B; Macapinlac HA; Lu Y Clin Nucl Med; 2019 Apr; 44(4):337-338. PubMed ID: 30688749 [TBL] [Abstract][Full Text] [Related]
18. [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases]. Tauber R; Gschwend J; Scheidhauer K; Eiber M; Krönke M Urologe A; 2017 Jan; 56(1):24-31. PubMed ID: 28058455 [TBL] [Abstract][Full Text] [Related]
19. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of bone metastases by 18F-choline PET/CT in a patient with castration-resistant prostate cancer treated with radium-223. Scalzi P; Baiocco C; Genovese S; Trevisan A; Sirotova Z; Poti C Urologia; 2017 Feb; 84(1):61-64. PubMed ID: 27911459 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]